WELLNESS STARTS WITH AWARENESS - CD8 T cells - The Body

More documents

Recommendations

Info

PA Online Poll Thanks to all of you who tuned in and commented on our daily blog from the AIDS 2008 conference in Mexico City. We really would love to hear from you as we expand our blog and community forum section at our newly redesigned website, www.positivelyaware.com. So, if you haven’t done so already, please register (it only takes a minute) and join in on the dialogue. Lots of interesting stuff going on—and lots more interesting stuff to come! No 12% Are you on HIV therapy? Yes = 88% No = 12% Special 20th Anniversary Issue in January/February July / August Poll Results Yes 88% Comments Are you currently taking any complementary or alternative therapy? Yes = 52% No = 48% · Many of us on HIV therapy are concerned about the long term eff ects of HIV therapy. Are there ongoing studies being conducted? [Editor’s note: Yes, to learn more visit www.clinicaltrials.gov. There are also many large, long term observational cohort studies such as MACS, VACS and WIHS.] · I am taking Atripla once a day. September / October Poll Question At the recent AIDS 2008 conference in Mexico City, there was talk about condom induced erectile dysfunction as a possible risk factor for HIV transmission (see Keith Green’s blog at www.positivelyaware.com). This month’s question: No 48% Have you or your partner ever experienced a loss of erection when using a condom? Vote at www.positivelyaware.com Yes 52% Positively Aware celebrates its 20th anniversary, going back to its origin as TPA News, with a special issue in January/February 2009. Th e annual drug guide will be published in March/April instead. If you have any reminiscences or updates about your experiences at TPAN or with Positively Aware that you’d like to share, especially from the early days, please submit them to publications@ tpan.com or to our mailing address by November 24. 14 PA • September / October 2008 • tpan.com • positivelyaware.com Positively Aware
AS PART OF HIV COMBINATION THERAPY: SUSTIVA ONCE-DAILY SUSTIVA IN HIV COMBINATION THERAPY: • Can help keep viral loads undetectable* for a long time † • Helps improve your body’s immune system by raising your T-cell count *Undetectable is defined as a viral load of less than 400 copies/mL or less than 50 copies/mL (depending on the test used). † Up to 168 weeks. IMPORTANT INFORMATION ABOUT SUSTIVA ® (efavirenz) INDICATION: SUSTIVA ® is a prescription medicine used in combination with other medicines to treat people who are infected with the human immunodeficiency virus type 1 (HIV-1). SUSTIVA does not cure HIV and has not been shown to prevent passing HIV to others. See your healthcare provider regularly. IMPORTANT SAFETY INFORMATION: Do not take SUSTIVA if you are taking the following medicines because serious and life-threatening side effects may occur when taken together: Hismanal ® (astemizole), Vascor ® (bepridil), Propulsid ® (cisapride), Versed ® (midazolam), Orap ® (pimozide), Halcion ® (triazolam), or ergot medicines (for example, Wigraine ® and Cafergot ® ). In addition, SUSTIVA should not be taken with: Vfend ® (voriconazole) since it may lose its effect or may increase the chance of having side effects from SUSTIVA. Some doses of voriconazole can be taken at the same time as a lower dose of SUSTIVA, but you must check with your doctor first. SUSTIVA should not be taken with ATRIPLA ® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) because it contains efavirenz, the active ingredient of SUSTIVA. Fortovase ® , Invirase ® (saquinavir mesylate) should not be used as the only protease inhibitor in combination with SUSTIVA. Taking SUSTIVA with St. John’s wort (Hypericum perforatum) is not recommended as it may cause decreased levels of SUSTIVA, & ME SUSTIVA does not cure HIV and has not been shown to prevent passing HIV to others. Individual results may vary. increased viral load, and possible resistance to SUSTIVA (efavirenz) or cross-resistance to other anti-HIV drugs. This list of medicines is not complete. Discuss with your healthcare provider all prescription and non-prescription medicines, vitamins, and herbal supplements you are taking or plan to take. Tell your healthcare provider right away if you have any side effects or conditions, including the following: •Severe depression, strange thoughts, or angry behavior have been reported by a small number of patients taking SUSTIVA. Some patients have had thoughts of suicide and a few have actually committed suicide. These problems may occur more often in patients who have had mental illness. •Dizziness, trouble sleeping or concentrating, drowsiness, unusual dreams, and/or hallucinations are common, and tend to go away after taking SUSTIVA for a few weeks. Symptoms were severe in a few patients and some patients discontinued therapy. These symptoms may become more severe with the use of alcohol and/or mood-altering (street) drugs. If you are dizzy, have trouble concentrating, and/or are drowsy, avoid activities that may be dangerous, such as driving or operating machinery. •If you have ever had mental illness or are using drugs or alcohol. •Pregnancy: Women should not become pregnant while taking SUSTIVA and for 12 weeks after stopping SUSTIVA. SUSTIVA and the SUNRISE logo are registered trademarks of Bristol-Myers Squibb Pharma Company. ATRIPLA is a trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. All other trademarks are owned by third parties. © 2008 Bristol-Myers Squibb Company, Princeton, NJ 08543 U.S.A. 692US08AB01101 05/08 Please see Patient Information about SUSTIVA on the next page. . .. We’re in this together. Ask your doctor if SUSTIVA is right for you. Visit www.sustiva.com Serious birth defects have been seen in children of women treated with SUSTIVA (efavirenz) during pregnancy. Therefore, women must use a reliable form of barrier contraception, such as a condom or diaphragm, even if they also use other methods of birth control. •Breast-Feeding: Women with HIV should not breast-feed because they can pass HIV through their milk to the baby. Also, SUSTIVA may pass through breast milk and cause serious harm to the baby. •Rash is a common side effect that usually goes away without any change in your medicines, but may be serious in a small number of patients. Rash may be a serious problem in some children. •If you have liver disease, your healthcare provider may want to do tests to check your liver. •Seizures have occurred in patients taking SUSTIVA, usually in those with a history of seizures. If you have ever had seizures, or take medicines for seizures, your healthcare provider may want to switch you to another medicine or monitor you. Changes in body fat have been seen in some patients taking anti-HIV medicines. The cause and long-term health effects are not known. Other common side effects of SUSTIVA taken with other anti-HIV medicines include: tiredness, upset stomach, vomiting, and diarrhea. You should take SUSTIVA on an empty stomach, preferably at bedtime, which may make some side effects less bothersome. SUSTIVA is one of several treatment options your doctor may consider. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Page 1 and 2: Positively Aware HIV Treatment and
Page 3 and 4: { Belief ��
Page 5 and 6: Type of Drug Examples of Generic Na
Page 7 and 8: Departments 6 TPAN Programs, Meetin
Page 9 and 10: Presenting ISENTRESS. A different w
Page 11 and 12: Photo © Russell McGonagle This Sho
Page 13: the utmost priority if we’re ever
Page 17 and 18: Photo © Russell McGonagle Drug lab
Page 19 and 20: Photo © Russell McGonagle Life Sav
Page 21 and 22: Photo © Russell McGonagle Bob Bowe
Page 23 and 24: Photos on this page provided by Bob
Page 25 and 26: ATRIPLA. The #1 prescribed complete
Page 27 and 28: These are not all the medicines tha
Page 29 and 30: hormone, that he had been injecting
Page 31 and 32: entirely due to swelling of hands a
Page 33 and 34: Methadone wellness Sarz Maxwell, M.
Page 35 and 36: Abuse and Mental Health Services Ad
Page 37 and 38: you have diabetes, hypertension, or
Page 39 and 40: “I borrowed my brother’s van, w
Page 41 and 42: was still crying soft ly. He opened
Page 43 and 44: Photos by Ron Baker Spotlight on Ho
Page 45 and 46: peutic dose range that should be he
Page 47 and 48: felt prepared. Little did I know th
Page 49 and 50: Comparing Two Integrase Inhibitors
Page 51 and 52: Non-violent resistance When resista
Page 53 and 54: Photo © Russell McGonagle And the
Page 55: Don’t lose yourself to HIV. Lipoa

WELLNESS STARTS WITH AWARENESS - CD8 T cells - The Body

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?